Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma

被引:18
|
作者
Wu, Lei [1 ]
Quan, Wen [1 ]
Luo, Qiong [2 ]
Pan, Ying [1 ]
Peng, Dongxu [1 ]
Zhang, Guihai [1 ]
机构
[1] Jinan Univ, Zhuhai Hosp, Zhuhai Peoples Hosp, Dept Oncol, Zhuhai, Peoples R China
[2] Southern Med Univ, Affiliated Zhuhai Hosp, Dept Oncol, Zhuhai, Peoples R China
关键词
hepatocellular carcinoma; PD-1; immune; HPD; PD-L1; DOWN-REGULATION; WEB SERVER; CANCER; MDM2; SURVIVAL; PROTEIN; LIVER;
D O I
10.3389/fmolb.2020.567950
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Liver hepatocellular carcinoma (LIHC) is the most prevalent primary cancer of the liver, and immune-related genes (IRGs) regulate its development. So far, there is still no precise biomarker that predicts response to immunotherapy in LIHC. Therefore, this research seeks to identify immunogenic prognostic biomarkers and explore potential predictors for the efficacy of anti-PD-1/PD-L1 therapies in LIHC. The clinical data and gene expression profiles of patients diagnosed with LIHC were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Moreover, IRGs were obtained from the ImmPort database. We discovered 35 IRGs that were differentially expressed between LIHC tissues and corresponding normal tissues. Through univariate Cox regression analysis, eight prognostic differentially expressed IRGs (PDEIRGs) were identified. Further, three optimal PDEIRGs (BIRC5, LPA, and ROBO1) were identified and used to construct a prognostic risk signature of LIHC patients via multivariate Cox regression analysis. The signature was validated by ROC curves. Subsequently, based on gene set enrichment analysis (GSEA) analysis, two out of the three optimal PDEIRGs (BIRC5 and LPA) were significantly enriched in the mismatch repair (MMR) pathway. Moreover, the two PDEIRGs (BIRC5 and LPA) were significantly correlated with the expression of genes related to mismatch repair (MLH1, MSH2, MSH6, and PMS2). Furthermore, correlations between the two PDEIRGs (BIRC5 and LPA) and immune checkpoints of cancer treatment (such as CTLA4, PD-1, and PD-L1) were demonstrated. Hyperprogressive disease (HPD) is a novel pattern of tumor progression which has a close relationship with immune checkpoint inhibitors (ICIs) utilization. MDM2 family amplification might promote the HPD phenomenon. Finally, we found a positive regulatory relationship between HPD related gene (MDM2) and BIRC5. Notably, MDM2 can either interact directly with BIRC5 or indirectly via downstream transcription factors of BIRC5. Overall, our study uncovered a novel 3-immune-related prognostic genes in LIHC.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma
    Zheng Wang
    Jie Zhu
    Yongjuan Liu
    Changhong Liu
    Wenqi Wang
    Fengzhe Chen
    Lixian Ma
    Journal of Translational Medicine, 18
  • [32] Construction of a prognostic model based on nine immune-related genes and identification of small molecule drugs for hepatocellular carcinoma (HCC)
    Zhang, Jiaxin
    Chen, Guang
    Zhang, Jiaying
    Zhang, Peng
    Ye, Yong'an
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2020, 12 (09): : 5108 - 5130
  • [33] Immune-related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma
    Zhang, Yaqiong
    Zhang, Liming
    Xu, Youwen
    Wu, Xiaoyu
    Zhou, Yong
    Mo, Jinggang
    JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (12) : 9304 - 9316
  • [34] Identification of prognostic and immune-related lncRNAs in hepatocellular carcinoma based on the cancer genome atlas data mining
    Ren, Kaikai
    Ma, Jiakang
    Zhou, Bo
    Lin, Xiaoyan
    Hou, Mingyu
    Zhang, Ling
    Yuan, Ling
    Ma, Jun
    MATERIALS EXPRESS, 2020, 10 (08) : 1189 - 1196
  • [35] Identification of immune-related genes and patient selection for hepatocellular carcinoma immunotherapy
    Chen, Zhen-Dong
    Luo, Jia-Yuan
    Ye, Yu-Ping
    Dang, Yi-Wu
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (05) : 1210 - +
  • [36] Identification and validation of redox-immune based prognostic signature for hepatocellular carcinoma
    Tu, Kangsheng
    Li, Jin
    Mo, Huanye
    Xian, Yao
    Xu, Qiuran
    Xiao, Xuelian
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2021, 18 (09): : 2030 - 2041
  • [37] Bioinformatics-Based Construction of Immune-Related microRNA and mRNA Prognostic Models for Hepatocellular Carcinoma
    Chen, Ying
    Yin, Dian
    Feng, Xiu
    He, Shennan
    Zhang, Liang
    Chen, Dongqin
    CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 1793 - 1811
  • [38] Identification and validation of an immune-related prognostic signature and key gene in papillary thyroid carcinoma
    Qin, Rujia
    Li, Chunyan
    Wang, Xuemin
    Zhong, Zhaoming
    Sun, Chuanzheng
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [39] Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma
    Rui Li
    Chen Jin
    Weiheng Zhao
    Rui Liang
    Huihua Xiong
    BMC Gastroenterology, 22
  • [40] Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma
    Li, Rui
    Jin, Chen
    Zhao, Weiheng
    Liang, Rui
    Xiong, Huihua
    BMC GASTROENTEROLOGY, 2022, 22 (01)